Gene Therapy: Moving Toward Commercialization, Insight Pharma Report

The latest report by Insight Pharma Report  “Gene Therapy: Moving Toward Commercialization”, outlines the progress of the gene therapy field since its inception in the 1970s, with a special focus on clinical-stage gene therapy programs that are aimed at commercialization, and the companies that are carrying out these programs.
In accord with the focus of this report, the firm has looked at:

Whether gene therapy can attain commercial success by the early-to-mid 2020s,
Which types of gene therapy programs have the greatest likelihood of success,
What hurdles might stand in the way of clinical and commercial success of leading gene therapy programs.
In addition to chapters that focus on various areas of commercial gene therapy, this report includes:
An expert interview with Sam Wadsworth, Ph.D., the Chief Scientific Officer of Dimension Therapeutics and former Head of Gene Therapy R&D at Genzyme.
Survey data from 88 researchers involved in gene therapy
Companies profiled: uniQure, Voyager Therapeutics, Oxford BioMedica, GeneQuine Therapeutics, Celladon Corporation, and bluebird

Click here to view the full press release.